stockrowBruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
Follow BRKR
Alert me
Bruker Corporation (BRKR) Return on equity
Bruker Corporation's return on equity over the twelve months to 30 September 2026 was −7.04%, down 6.0 percentage points from fiscal 2025 (−1.05%). Over the past ten years it has ranged from −1.05% (fiscal 2025) to 33.9% (fiscal 2023) — the current reading is the lowest in ten years. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −1.05% | (8.14) |
| FY2024 | 7.09% | (26.81) |
| FY2023 | 33.9% | 7.06 |
| FY2022 | 26.8% | (0.08) |
| FY2021 | 26.9% | 10.23 |
| FY2020 | 16.7% | (4.95) |
| FY2019 | 21.6% | (0.29) |
| FY2018 | 21.9% | 10.91 |
| FY2017 | 11.0% | (10.52) |
| FY2016 | 21.5% | 8.03 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PODD Insulet Corporation compare | 28.9% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| GMED Globus Medical, Inc. compare | 12.1% |
| PEN Penumbra, Inc. compare | 10.7% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation | −7.04% |
| TXG 10x Genomics compare | −9.40% |
| GKOS Glaukos Corporation compare | −22.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BRKR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement